Viewing Study NCT05219266

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:37 PM
Ignite Modification Date: 2026-06-08 @ 4:57 PM
Study NCT ID: NCT05219266
Status: NO_LONGER_AVAILABLE
Last Update Posted: 2024-06-28
First Post: 2021-10-05
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Managed Access Programs for PKC412, Midostaurin
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia View
None Acute Myeloid Leukemia View
None Aggressive Systemic Mastocytosis View
None Mast Cell Leukemia View
None Systemic Mastocytosis With an Associated Hematologic Neoplasm View
Keywords:

Keywords

Keyword Brief Keyword Text View
None FLT3-mutated AML View
None AML View
None Aggressive systemic mastocytosis View
None Mast cell leukemia View
None Systemic mastocytosis with an associated hematologic neoplasm View
None MAP View
None Manage access program View
None PKC412 View
None Midostaurin View